Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600380'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 9.54 Med: 11.74 Max: 40.69
Current: 9.99
During the past 13 years, Joincare Pharmaceutical Group Industry Co's highest Return-on-Tangible-Equity was 40.69%. The lowest was 9.54%. And the median was 11.74%.
SHSE:600380's Return-on-Tangible-Equity is ranked better than 57.27% of 894
companies
in the Drug Manufacturers industry
Industry Median: 7.785
vs SHSE:600380: 9.99
Joincare Pharmaceutical Group Industry Co (SHSE:600380) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Joincare Pharmaceutical Group Industry Co Return-on-Tangible-Equity Related Terms
Joincare Pharmaceutical Group Industry Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co Return-on-Tangible-Equity Chart
Joincare Pharmaceutical Group Industry Co Annual Data
SHSE:600380 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Joincare Pharmaceutical Group Industry Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joincare Pharmaceutical Group Industry Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Joincare Pharmaceutical Group Industry Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Joincare Pharmaceutical Group Industry Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.28% mean?
Joincare Pharmaceutical Group Industry Co (SHSE:600380) has a Return-on-Tangible-Equity of 12.28% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. This is near median its historical median of 11.74. Over the past decade, Joincare Pharmaceutical Group Industry Co's Return-on-Tangible-Equity has ranged from 9.54 to 40.69. According to the industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #382 out of 894 companies in the Drug Manufacturers industry, placing it in the top 42.7%.
Is Joincare Pharmaceutical Group Industry Co's Return-on-Tangible-Equity too high?
Joincare Pharmaceutical Group Industry Co's current Return-on-Tangible-Equity of 12.28% is near median its 10-year median of 11.74. Over the past 10 years, this metric has ranged from a low of 9.54 to a high of 40.69. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.79. Joincare Pharmaceutical Group Industry Co's value of 12.28% is 57.7% above this industry median. Based on the distribution chart, Joincare Pharmaceutical Group Industry Co ranks #382 out of 894 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #382 out of 894 companies for Return-on-Tangible-Equity. This puts Joincare Pharmaceutical Group Industry Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.79. Joincare Pharmaceutical Group Industry Co's value of 12.28% is 57.7% above this benchmark. Historically, Joincare Pharmaceutical Group Industry Co's own Return-on-Tangible-Equity has ranged from 9.54 to 40.69 over the past decade. While the company's 10-year median is 11.74 vs. the industry median of 7.79, Joincare Pharmaceutical Group Industry Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.79, based on 894 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joincare Pharmaceutical Group Industry Co's current Return-on-Tangible-Equity of 12.28% is 57.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joincare Pharmaceutical Group Industry Co's current Return-on-Tangible-Equity is 12.28%, which is near median its own 10-year median of 11.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co (SHSE:600380) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥11.82, compared to a current price of ¥10.35 — trading 12.4% below its estimated fair value. The current Return-on-Tangible-Equity is 12.28%, which is near median its 10-year median of 11.74 and 57.7% above the Drug Manufacturers industry median of 7.79. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (SHSE:600380), the current Return-on-Tangible-Equity is 12.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joincare Pharmaceutical Group Industry Co (SHSE:600380) Overvalued in 2026?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued.
The current stock price of ¥10.35 is trading 12.4% below its estimated GF Value™ of ¥11.82.
GuruFocus considers Joincare Pharmaceutical Group Industry Co to be Modestly Undervalued.
Key valuation signals for SHSE:600380:
Return-on-Tangible-Equity: 12.28% (near median its 10-year median of 11.74)
GF Value™: ¥11.82 vs. price of ¥10.35 (12.4% below fair value)
Industry Position: 57.7% above the Drug Manufacturers median (#382 of 894)
No single metric tells the full story. See the SHSE:600380 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
80GF Score
Get the complete analysis for SHSE:600380
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600380 has been successfully added to your 
